Descripción de la empresa
InflaRx N.V. operates as a clinical-stage biopharmaceutical entity dedicated to the discovery and development of inhibitors utilizing C5a technology within Germany and the United States. The company focuses its research on C5a, an inflammatory mediator designed to treat a variety of autoimmune and other inflammatory diseases, positioning it within the specialized healthcare sector. Specifically, InflaRx functions within the biotechnology industry, a segment characterized by high research and development expenditures and a reliance on intellectual property for competitive advantage. The company currently employs 65 individuals and maintains a total market capitalization of $69.92M, generating annual revenue of $29,331. These financial figures indicate that the company operates on a micro-cap scale with minimal revenue generation relative to its market valuation, suggesting a position typical of early-stage development firms where value is derived primarily from potential future product approvals rather than current commercial sales.
Salud financiera
InflaRx N.V. reported revenue of $29,331 over the trailing twelve months, yet recorded a net income of $-45,633,780 and an EBITDA of $-48,198,212. The significant disparity between the negligible revenue and the substantial negative net income reveals a cost structure dominated by operational expenses, likely including extensive research and development activities and general corporate overhead that far exceed current sales. The company's free cash flow stands at $-14,833,020, indicating a continuous burn rate that consumes available liquidity and limits immediate financial flexibility without external capital injections. Margin analysis presents a complex picture with a gross margin of 0.0%, an operating margin of 37898.3%, and a profit margin of 0.0%, where the anomalous operating margin figure suggests accounting adjustments or specific classification of costs that distort traditional profitability interpretations. On the liability side, the company holds $46.46M in cash against $897,916 in debt, resulting in a debt-to-equity ratio of 2.16. Despite the elevated debt-to-equity metric, the balance sheet appears less leveraged in practical terms given the substantial cash reserves available to service obligations. Liquidity is further supported by a current ratio of 4.13, which indicates a robust ability to meet short-term obligations with current assets. However, the return on equity of -88.6% and return on assets of -46.0% demonstrate that management is currently generating negative returns on both shareholder capital and total assets, reflecting the inherent losses of a clinical-stage biotechnology firm prior to commercialization.
Evaluación de valoración
The valuation metrics for InflaRx N.V. show a P/E ratio (TTM) as N/A due to negative earnings, while the forward P/E is listed at -1.30, a figure that implies earnings are currently negative and prevents standard forward earnings multiples from providing a conventional valuation framework. The price-to-book ratio stands at 1.45, indicating that the market values the company at 1.45 times its book value, which suggests a premium assigned to the firm's intangible assets and future clinical potential despite its lack of current profitability. Alternative valuation measures include a price-to-sales ratio of 2383.88 and an EV/EBITDA of -0.51, metrics that highlight the extreme disconnect between current market capitalization and the company's minimal revenue base, signaling that the stock price is driven almost entirely by speculative expectations of future success. Price momentum is observed within a 52-week range bounded by a high of $1.94 and a low of $0.71, meaning the current trading price sits between these extremes and reflects the high volatility inherent in clinical-stage biotech securities. The beta value of 1.51 indicates that the stock exhibits price volatility 51% higher than the broader market, underscoring the significant risk premium investors demand for holding a highly leveraged and speculative asset class.
Growth & Income
InflaRx N.V. displays N/A for revenue growth year-over-year and N/A for earnings growth year-over-year, as the company has not yet generated sufficient commercial revenue to calculate meaningful growth percentages. The absence of positive earnings growth relative to revenue is expected for a firm with $29,331 in revenue and massive negative net income, implying that the business is still in the pre-revenue or early revenue stage where growth rates are not yet applicable in traditional metrics. Regarding income distribution, the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the company retains all earnings, or rather, reinvests its cash reserves and any future operating income directly into research and development efforts rather than distributing cash to shareholders. The overall growth and income profile is characterized by zero current profitability and zero dividend yield, presenting a pure growth-at-any-cost scenario where investors seek capital appreciation from potential future drug approvals rather than current income or stable earnings expansion.